recombinant dna in medicine industry- monoclonal antibodies topics in nanobiotechnology- april 2004-...
TRANSCRIPT
Recombinant DNA in Medicine Industry- Monoclonal Antibodies
Topics in Nanobiotechnology- April 2004- Maria Viviana Duarte
Introduction
Topics in Nanobiotechnology- April 2004- Maria Viviana Duarte
As soon as first successful cloning experiments were reported in 1973, applications for this powerful technology quickly followed-
Proteins were produced through recombinant DNA technology for :
•Somatostatin (1976)- 14 aminoacids peptide neurtransmitter
*Treatment of numerous diseases
•Insulin for the treatment of diabetes
•Human Growth Hormone
•Food Production
•MAb development
•etc
Expression Systems are developed to Produce Recombinant Proteins
Topics in Nanobiotechnology- April 2004- Maria Viviana Duarte
Cloning the gene or cDNA encoding a particular proteins is only the first of many steps needed to produce a recombinant protein
Next step: put he gene into a host cell for production
Topics in Nanobiotechnology- April 2004- Maria Viviana Duarte
The choice of which cell is used dependes on the project goal and on the properties of the protein to be produced
Expression system
Positive Negative
Bacterial cells(B. subtilis)
SimplicityShort generation timesLarge yields of productCan be induced to secrete the product into the culture mediumEj: Bacterial production of human growth hormone (hGH)
Although some proteins are expressed to high levels, they often the fail to fold properly and form insoluble inclusion bodiesForeign proteins are sometimes toxic to bacteriaLack enzymes that are present in eukaryotic cells and add posttranslational modifications (phosphates, sugars)
Yeast Simple eukaryote that resembles mammalian cells in may ways but can be grown as quickly and cheaply as bacteria canCan be induced to secrete the product into the culture mediumPerform posttranslational modifications
Active proteases that degrade foreign proteins (reducing yield of product)
Insects cell by baculovirus vectors
High level expressionCorrect foldingPosttranslational modificationsEj: Vaccine for the AIDS virus has been prepared by producing on of the HIV glycoproteins with this system
Higher costs than bacteria and yeast, but lower than mammal cells
Mammalian cells
Checking the function of a newly cloned gene and as a quick methods for assessing the function of engineered proteins.Ej: large scale production for proteins such as tissue plasmoninogen activator
CostStill in development
Expression Systems
Monoclonal Antibodies Function
Topics in Nanobiotechnology- April 2004- Maria Viviana Duarte
•Antibodies are exquisitely selective proteins that can bind to a single target among millions of irrelevant sites
•Could effectively seek and destroy tumor cells and infectious agents wherever the reside
Producing a useful antibody in large quantities
Major limitation in the therapeutic use of antibodies
Researchers tested myelomas
Topics in Nanobiotechnology- April 2004- Maria Viviana Duarte
Lack to produce an antibody to their specifications
Reserchers tested myelomas
Hybridoma- produce antibodies specified by the lymphocyte from the immunized animal
Development of monoclonal antibody technology
•Monoclonal antibodies are already widely used for the diagnostic of infections and cancer and for the imaging of tumors for radiotherapy
•Preparing specfic antibodies: abzyme- antibodies with catalytic activity, birecognition, etc
Hybridoma
Topics in Nanobiotechnology- April 2004- Maria Viviana Duarte
Recombinant DNA- Watson, Gilman, Witkowski, Zoller. Scientific American Books. 1992
Topics in Nanobiotechnology- April 2004- Maria Viviana Duarte
Recombinant DNA- Watson, Gilman, Witkowski, Zoller. Scientific American Books. 1992
Bypassing fusion step
Direct cloning antibody cDNAs from the lymphocytes of immunized mice
More Monoclonal antibodyes
Topics in Nanobiotechnology- April 2004- Maria Viviana Duarte
Humanized MAb
Bispecific antibodies
Effector Domains modification
More Monoclonal antibodyes- Humanized
Topics in Nanobiotechnology- April 2004- Maria Viviana Duarte
Humanized monoclonal antibodies
Monoclonal antibodies Usually mouse protein
What about this foreing proteins in human system?
Humanized monoclonal antibodies
Topics in Nanobiotechnology- April 2004- Maria Viviana Duarte
The variable regions differ in sequence from on antiblody to another, this is the region of the protein that binds the antigen
First method: encoded proteins in which the variable regions from the mouse antibody were fused the constant regions from a human antibody
Not fully humanized
Recombinant DNA- Watson, Gilman, Witkowski, Zoller. Scientific American Books. 1992
Humanized monoclonal antibodies
Topics in Nanobiotechnology- April 2004- Maria Viviana Duarte
Humanized MAb in clinical trials as an immunosuppressant and for treatment of lymphoid tumors.
Few of the hundred aminoacids in Variable region contact the antigen (complementary determining regions CDRs)
Just CDR to be transferred
Humanized monoclonal antibodies
Topics in Nanobiotechnology- April 2004- Maria Viviana Duarte
Review articleSupported by a grant from Zeneca PharmaceuticalsHumanized antibodies as potentialtherapeutic drugsSurender K Vaswani, MD and Robert G Hamilton, PhD
Bispecific antibodies
Topics in Nanobiotechnology- April 2004- Maria Viviana Duarte
Bispecific antibodies in cancer therapy.
Segal DM, Weiner GJ, Weiner LM.
Immune Targeting Section, Experimental Immunology Branch, National Cancer Institute, Building 10 Room 4B36, National Institutes of Health, Bethesda, MD 20892-1360, USA. [email protected]
Based upon in vitro and animal studies, a number of Phase I and II clinical trials have been initiated to test whether bispecific antibodies could redirect immune effectors against tumor cells in cancer patients. Recently, results from those trials showed beneficial effects in some patients but it is clear many problems remain to be solved. In addition, molecular engineering approaches are providing new and improved sources of clinically relevant bispecific antibodies.
http://users.telenet.be/nmertens/U11/IM_bispecific_antibodies.htm